Isoliquiritigenin Inhibits Interferon-γ-Inducible Genes Expression in Hepatocytes through Down-Regulating Activation of JAK1/STAT1, IRF3/MyD88, ERK/MAPK, JNK/MAPK and PI3K/Akt Signaling Pathways

Cellular Physiology and Biochemistry

Volumn 37, Issue 2, 2015, Pages 501-514

  Wu, Shanshan ^a   Xue, Jihua ^b   Yang, Ying ^a   Zhu, Haihong ^a   Chen, Feng ^a   Wang, Jing ^a   Lou, Guohua ^a   Liu, Yanning ^a   Shi, Yixian ^a   Yu, Ye ^a   Xia, Caixia ^a   Hu, Ying ^a   Chen, Zhi ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Chemokine; CXCR3; HepG2; Interferon inducible genes; Isoliquiritigenin; L02

Indexed keywords

CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 6; ISOLIQUIRITIGENIN; JANUS KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT1 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; CHALCONE DERIVATIVE; CHEMOKINE; ENZYME INHIBITOR; PROTEIN KINASE;

ARTICLE; CELL COUNTING; CELL VIABILITY; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GENE; GENE EXPRESSION REGULATION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERFERON GAMMA INDUCIBLE GENE; MOLECULAR MECHANICS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CELL LINE; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HEPG2 CELL LINE; LIVER CELL; METABOLISM;

CELL LINE; CELL SURVIVAL; CHALCONES; CHEMOKINES; ENZYME INHIBITORS; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEP G2 CELLS; HEPATOCYTES; HUMANS; INTERFERON-GAMMA; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 84940778657     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000430372     Document Type: Article

References (46)

1. Zeremski M, Petrovic LM, Chiriboga L, Brown QB, Yee HT, Kinkhabwala M, Jacobson IM, Dimova R, Markatou M, Talal AH: Intrahepatic levels of cxcr3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis c. Hepatology 2008;48:1440-1450.
2. Wasmuth HE, Tacke F, Trautwein C: Chemokines in liver inflammation and fibrosis. Semin Liver Dis 2010;30:215-225.
3. Campbell JD, Gangur V, Simons FE, HayGlass KT: Allergic humans are hyporesponsive to a cxcr3 ligandmediated th1 immunity-promoting loop. FASEB J 2004;18:329-331.
4. Indraccolo S, Pfeffer U, Minuzzo S, Esposito G, Roni V, Mandruzzato S, Ferrari N, Anfosso L, Dell'Eva R, Noonan DM, Chieco-Bianchi L, Albini A, Amadori A: Identification of genes selectively regulated by ifns in endothelial cells. J Immunol 2007;178:1122-1135.
5. Manousou P, Kolios G, Drygiannakis I, Koulentaki M, Pyrovolaki K, Voumvouraki A, Notas G, Bourikas L, Papadaki HA, Kouroumalis E: Cxcr3 axis in patients with primary biliary cirrhosis: A possible novel mechanism of the effect of ursodeoxycholic acid. Clin Exp Immunol 2013;172:9-15.
6. Friedman BH, Wolf JH, Wang L, Putt ME, Shaked A, Christie JD, Hancock WW, Olthoff KM: Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation. Liver Transpl 2012;18:166-176.
7. Helbig KJ, Ruszkiewicz A, Semendric L, Harley HA, McColl SR, Beard MR: Expression of the cxcr3 ligand i-tac by hepatocytes in chronic hepatitis c and its correlation with hepatic inflammation. Hepatology 2004;39:1220-1229.
8. Clark-Lewis I, Mattioli I, Gong JH, Loetscher P: Structure-function relationship between the human chemokine receptor cxcr3 and its ligands. J Biol Chem 2003;278:289-295.
9. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P: An alternatively spliced variant of cxcr3 mediates the inhibition of endothelial cell growth induced by ip-10, mig, and i-tac, and acts as functional receptor for platelet factor 4. J Exp Med 2003;197:1537-1549.
10. Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH: Chemokine and chemokine receptor interactions provide a mechanism for selective t cell recruitment to specific liver compartments within hepatitis c-infected liver. J Immunol 1999;163:6236-6243.
11. Fahey S, Dempsey E, Long A: The role of chemokines in acute and chronic hepatitis c infection. Cell Mol Immunol 2014;11:25-40.
12. Chuang YH, Lian ZX, Cheng CM, Lan RY, Yang GX, Moritoki Y, Chiang BL, Ansari AA, Tsuneyama K, Coppel RL, Gershwin ME: Increased levels of chemokine receptor cxcr3 and chemokines ip-10 and mig in patients with primary biliary cirrhosis and their first degree relatives. J Autoimmun 2005;25:126-132.
13. Apolinario A, Majano PL, Alvarez-Perez E, Saez A, Lozano C, Vargas J, Garcia-Monzon C: Increased expression of t cell chemokines and their receptors in chronic hepatitis c: Relationship with the histological activity of liver disease. Am J Gastroenterol 2002;97:2861-2870.
14. Zhai Y, Shen XD, Gao F, Zhao A, Freitas MC, Lassman C, Luster AD, Busuttil RW, Kupiec-Weglinski JW: Cxcl10 regulates liver innate immune response against ischemia and reperfusion injury. Hepatology 2008;47:207-214.
15. Zeremski M, Dimova R, Astemborski J, Thomas DL, Talal AH: Cxcl9 and cxcl10 chemokines as predictors of liver fibrosis in a cohort of primarily african-american injection drug users with chronic hepatitis c. J Infect Dis 2011;204:832-836.
16. Tacke F, Zimmermann HW, Berres ML, Trautwein C, Wasmuth HE: Serum chemokine receptor cxcr3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases. Liver Int 2011;31:840-849.
17. Berres ML, Asmacher S, Lehmann J, Jansen C, Gortzen J, Klein S, Meyer C, Strunk HM, Fimmers R, Tacke F, Strassburg CP, Trautwein C, Sauerbruch T, Wasmuth HE, Trebicka J: Cxcl9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. J Hepatol 2015;62:332-339.
18. Harvey CE, Post JJ, Palladinetti P, Freeman AJ, Ffrench RA, Kumar RK, Marinos G, Lloyd AR: Expression of the chemokine ip-10 (cxcl10) by hepatocytes in chronic hepatitis c virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 2003;74:360-369.
19. Zhang X, Shen J, Man K, Chu ES, Yau TO, Sung JC, Go MY, Deng J, Lu L, Wong VW, Sung JJ, Farrell G, Yu J: Cxcl10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis. J Hepatol 2014;61:1365-1375.
20. Zeremski M, Dimova R, Brown Q, Jacobson IM, Markatou M, Talal AH: Peripheral cxcr3-associated chemokines as biomarkers of fibrosis in chronic hepatitis c virus infection. J Infect Dis 2009;200:1774-1780.
21. Zimmermann HW, Tacke F: Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm Allergy Drug Targets 2011;10:509-536.
22. Hintermann E, Bayer M, Pfeilschifter JM, Luster AD, Christen U: Cxcl10 promotes liver fibrosis by prevention of nk cell mediated hepatic stellate cell inactivation. J Autoimmun 2010;35:424-435.
23. Sahin H, Borkham-Kamphorst E, Kuppe C, Zaldivar MM, Grouls C, Al-samman M, Nellen A, Schmitz P, Heinrichs D, Berres ML, Doleschel D, Scholten D, Weiskirchen R, Moeller MJ, Kiessling F, Trautwein C, Wasmuth HE: Chemokine cxcl9 attenuates liver fibrosis-associated angiogenesis in mice. Hepatology 2012;55:1610-1619.
24. Yoneyama H, Kai Y, Koyama J, Suzuki K, Kawachi H, Narumi S, Ichida T: Neutralization of cxcl10 accelerates liver regeneration in carbon tetrachloride-induced acute liver injury. Med Mol Morphol 2007;40:191-197.
25. Hou FQ, Wu XJ, Wang Y, Chen J, Liu YZ, Ren YY, Song G, Ding YP, Yu M, Wang GQ: Rapid downregulation of programmed death-1 and interferon-gamma-inducible protein-10 expression is associated with favourable outcome during antiviral treatment of chronic hepatitis b. J Viral Hepat 2013;20:18-26.
26. Zhang X, Yeung ED, Wang J, Panzhinskiy EE, Tong C, Li W, Li J: Isoliquiritigenin, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer cells. Clin Exp Pharmacol Physiol 2010;37:841-847.
27. Kim JY, Park SJ, Yun KJ, Cho YW, Park HJ, Lee KT: Isoliquiritigenin isolated from the roots of glycyrrhiza uralensis inhibits lps-induced inos and cox-2 expression via the attenuation of nf-kappab in raw 264.7 macrophages. Eur J Pharmacol 2008;584:175-184.
28. Tawata M, Aida K, Noguchi T, Ozaki Y, Kume S, Sasaki H, Chin M, Onaya T: Anti-platelet action of isoliquiritigenin, an aldose reductase inhibitor in licorice. Eur J Pharmacol 1992;212:87-92.
29. Lee CK, Son SH, Park KK, Park JH, Lim SS, Chung WY: Isoliquiritigenin inhibits tumor growth and protects the kidney and liver against chemotherapy-induced toxicity in a mouse xenograft model of colon carcinoma. J Pharmacol Sci 2008;106:444-451.
30. Qin Q, Zuo Y, Yang X, Lu J, Zhan L, Xu L, Zhang C, Zhu H, Liu J, Liu Z, Tao G, Dai S, Zhang X, Ma J, Cai J, Sun X: Smac mimetic compound lcl161 sensitizes esophageal carcinoma cells to radiotherapy by inhibiting the expression of inhibitor of apoptosis protein. Tumour Biol 2014;35:2565-2574.
31. Nguyen N, de Esch C, Cameron B, Kumar RK, Zekry A, Lloyd AR: Positioning of leukocyte subsets in the portal and lobular compartments of hepatitis c virus-infected liver correlates with local chemokine expression. J Gastroenterol Hepatol 2014;29:860-869.
32. Apolinario A, Majano PL, Lorente R, Nunez O, Clemente G, Garcia-Monzon C: Gene expression profile of t-cell-specific chemokines in human hepatocyte-derived cells: Evidence for a synergistic inducer effect of cytokines and hepatitis c virus proteins. J Viral Hepat 2005;12:27-37.
33. Berres ML, Trautwein C, Schmeding M, Eurich D, Tacke F, Bahra M, Neuhaus P, Neumann UP, Wasmuth HE: Serum chemokine cxc ligand 10 (cxcl10) predicts fibrosis progression after liver transplantation for hepatitis c infection. Hepatology 2011;53:596-603.
34. Antonelli A, Ferri C, Ferrari SM, Colaci M, Fallahi P: Immunopathogenesis of hcv-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun Rev 2008;8:18-23.
35. Adianti M, Aoki C, Komoto M, Deng L, Shoji I, Wahyuni TS, Lusida MI, Soetjipto, Fuchino H, Kawahara N, Hotta H: Anti-hepatitis c virus compounds obtained from glycyrrhiza uralensis and other glycyrrhiza species. Microbiol Immunol 2014;58:180-187.
36. Clarke DL, Clifford RL, Jindarat S, Proud D, Pang L, Belvisi M, Knox AJ: Tnfalpha and ifngamma synergistically enhance transcriptional activation of cxcl10 in human airway smooth muscle cells via stat-1, nf-kappab, and the transcriptional coactivator creb-binding protein. J Biol Chem 2010;285:29101-29110.
37. Zhou Y, Wang S, Ma JW, Lei Z, Zhu HF, Lei P, Yang ZS, Zhang B, Yao XX, Shi C, Sun LF, Wu XW, Ning Q, Shen GX, Huang B: Hepatitis b virus protein x-induced expression of the cxc chemokine ip-10 is mediated through activation of nf-kappab and increases migration of leukocytes. J Biol Chem 2010;285:12159-12168.
38. Brownell J, Bruckner J, Wagoner J, Thomas E, Loo YM, Gale M, Jr., Liang TJ, Polyak SJ: Direct, interferonindependent activation of the cxcl10 promoter by nf-kappab and interferon regulatory factor 3 during hepatitis c virus infection. J Virol 2014;88:1582-1590.
39. Sun D, Ding A: Myd88-mediated stabilization of interferon-gamma-induced cytokine and chemokine mrna. Nat Immunol 2006;7:375-381.
40. Shen Q, Zhang R, Bhat NR: Map kinase regulation of ip10/cxcl10 chemokine gene expression in microglial cells. Brain Res 2006;1086:9-16.
41. Petrai I, Rombouts K, Lasagni L, Annunziato F, Cosmi L, Romanelli RG, Sagrinati C, Mazzinghi B, Pinzani M, Romagnani S, Romagnani P, Marra F: Activation of p38(mapk) mediates the angiostatic effect of the chemokine receptor cxcr3-b. Int J Biochem Cell Biol 2008;40:1764-1774.
42. Nakamichi K, Inoue S, Takasaki T, Morimoto K, Kurane I: Rabies virus stimulates nitric oxide production and cxc chemokine ligand 10 expression in macrophages through activation of extracellular signalregulated kinases 1 and 2. J Virol 2004;78:9376-9388.
43. Shahabuddin S, Ji R, Wang P, Brailoiu E, Dun N, Yang Y, Aksoy MO, Kelsen SG: Cxcr3 chemokine receptorinduced chemotaxis in human airway epithelial cells: Role of p38 mapk and pi3k signaling pathways. Am J Physiol Cell Physiol 2006;291:C34-39.
44. Mendez-Samperio P, Perez A, Rivera L: Mycobacterium bovis bacillus calmette-guerin (bcg)-induced activation of pi3k/akt and nf-kb signaling pathways regulates expression of cxcl10 in epithelial cells. Cell Immunol 2009;256:12-18.
45. Li Y, Zhao H, Wang Y, Zheng H, Yu W, Chai H, Zhang J, Falck JR, Guo AM, Yue J, Peng R, Yang J: Isoliquiritigenin induces growth inhibition and apoptosis through downregulating arachidonic acid metabolic network and the deactivation of pi3k/akt in human breast cancer. Toxicol Appl Pharmacol 2013;272:37-48.
46. Kang SW, Choi JS, Choi YJ, Bae JY, Li J, Kim DS, Kim JL, Shin SY, Lee YJ, Kwun IS, Kang YH: Licorice isoliquiritigenin dampens angiogenic activity via inhibition of mapk-responsive signaling pathways leading to induction of matrix metalloproteinases. J Nutr Biochem 2010;21:55-65.